Back to Search Start Over

Co‐occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome

Authors :
Universidad de Alicante. Departamento de Biotecnología
Ferrer‐Avargues, Rosario
Castillejo, María Isabel
Dámaso, Estela
Díez‐Obrero, Virginia
Garrigos, Noemí
Molina, Tatiana
Codoñer‐Alejos, Alan
Segura, Ángel
Sánchez‐Heras, Ana Beatriz
Castillejo, Adela
Soto, José Luis
Universidad de Alicante. Departamento de Biotecnología
Ferrer‐Avargues, Rosario
Castillejo, María Isabel
Dámaso, Estela
Díez‐Obrero, Virginia
Garrigos, Noemí
Molina, Tatiana
Codoñer‐Alejos, Alan
Segura, Ángel
Sánchez‐Heras, Ana Beatriz
Castillejo, Adela
Soto, José Luis
Publication Year :
2021

Abstract

Background: Lynch syndrome (LS) is a hereditary condition characterized by a high risk of colorectal cancer, endometrial cancer, and other neoplasia associated with germline alterations in DNA mismatch repair genes. The classical genetic diagnostic strategy for LS consists of the Sanger sequencing of genes associated with the suspected syndrome. Next‐generation sequencing (NGS) enables the simultaneous sequencing of a large number of hereditary cancer genes. Here, we aimed to study whether other germline pathogenic variants of hereditary cancer genes are present in patients with LS. Methods: A cohort of 84 probands with a previous genetic diagnosis of LS by Sanger sequencing was reanalyzed using NGS via a commercial panel of 94 hereditary cancer genes by hybrid capture. The American College of Medical Genetics and Genomics criteria were used to classify the clinical significance of the variants. The findings of NGS were confirmed by Sanger sequencing. When possible, genetic analyses of the new findings in the proband's relatives were also performed by Sanger sequencing. Results: We identified five families (6%), out of 84, with at least two germline pathogenic variants conferring to high or moderate risk in different dominant cancer‐predisposing genes: [MLH1‐BRCA2‐NBN], [MLH1‐BRCA1], [MSH2‐ATM], [MSH6‐NF1], and [MLH1‐FANCA]. Interestingly, only one out of these five families exhibited a clinical phenotype associated with the new pathogenic variants. The family with three pathogenic variants of the [MLH1‐BRCA2‐NBN] genes showed a high aggregation of tumors associated with LS and breast and ovarian cancer syndrome. Conclusions: Our results showed that the co‐occurrence of more than one pathogenic variant in cancer‐predisposing genes was remarkable among cases of LS. In most cases, no clinicial manifestations were associated with the secondary pathogenic variants. Further studies are needed to confirm these findings and elucidate their clinical impact. Reanalysis of LS

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1257405094
Document Type :
Electronic Resource